18Fluorodeoxyglucose-positron emission tomography/computed tomography for differentiation of renal tumors in hereditary kidney cancer syndromes
Tóm tắt
To assess differences in FDG-PET/CT uptake among four subtypes of renal tumors: clear cell RCC (ccRCC), papillary type I and II RCC (pRCC), and oncocytoma. This retrospective study investigated 33 patients with 98 hereditary renal tumors. Lesions greater than 1 cm and patients with a timeframe of less than 18 months between preoperative imaging and surgery were considered. FDG-PET/CT images were independently reviewed by two nuclear medicine physicians, blinded to clinical information. Volumetric lesion SUVmean was measured and used to calculate a target-to-background ratio respective to liver (TBR). The Shrout-Fleiss intra-class correlation coefficient was used to assess reliability between readers. A linear mixed effects model, accounting for within-patient correlations, was used to compare TBR values of primary renal lesions with and without distant metastasis. The time interval between imaging and surgery for all tumors had a median of 77 (Mean: 139; Range: 1–512) days. Intra-class reliability of mean TBR resulted in a mean κ score of 0.93, indicating strong agreement between the readers. The mixed model showed a significant difference in mean TBR among the subtypes (p < 0.0001). Pairwise comparison showed significant differences between pRCC type II and ccRCC (p < 0.0001), pRCC type II and pRCC type I (p = 0.0001), and pRCC type II and oncocytoma (p = 0.0016). Furthermore, a significant difference in FDG uptake was present between primary pRCC type II renal lesions with and without distant metastasis (p = 0.023). pRCC type II lesions demonstrated significantly higher FDG activity than ccRCC, pRCC type I, or oncocytoma. These findings indicate that FDG may prove useful in studying the metabolic activity of renal neoplasms, identifying lesions of highest clinical concern, and ultimately optimizing active surveillance, and personalizing management plans.
Tài liệu tham khảo
Mytsyk Y, Dutka I, Borys Y, Komnatska I, Shatynska-Mytsyk I, Farooqi AA, et al. Renal cell carcinoma: applicability of the apparent coefficient of the diffusion-weighted estimated by MRI for improving their differential diagnosis, histologic subtyping, and differentiation grade. International urology and nephrology. 2017;49(2):215–24.
Yu X, Lin M, Ouyang H, Zhou C, Zhang H. Application of ADC measurement in characterization of renal cell carcinomas with different pathological types and grades by 3.0 T diffusion-weighted MRI. European journal of radiology. 2012;81(11):3061–6.
Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nature reviews Disease primers. 2017;3:17009.
Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003;170(6 Pt 1):2163–72.
Linehan WM. Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res. 2012;22(11):2089–100.
Schmidt LS, Linehan WM. Genetic predisposition to kidney cancer. Semin Oncol. 2016;43(5):566–74.
Lassel E, Rao R, Schwenke C, Schoenberg S, Michaely H. Diffusion-weighted imaging of focal renal lesions: a meta-analysis. European radiology. 2014;24(1):241–9.
Filippiadis D, Mauri G, Marra P, Charalampopoulos G, Gennaro N, De Cobelli FJIJoH. Percutaneous ablation techniques for renal cell carcinoma: current status and future trends. 2019;36(2):21–30.
Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. European urology. 2015;67(5):913–24.
Agnello F, Roy C, Bazille G, Galia M, Midiri M, Charles T, et al. Small solid renal masses: characterization by diffusion-weighted MRI at 3 T. Clinical radiology. 2013;68(6):e301-e8.
Hötker AM, Mazaheri Y, Wibmer A, Zheng J, Moskowitz CS, Tickoo SK, et al. Use of DWI in the differentiation of renal cortical tumors. American Journal of Roentgenology. 2016;206(1):100–5.
Doshi AM, Huang WC, Donin NM, Chandarana H. MRI features of renal cell carcinoma that predict favorable clinicopathologic outcomes. American Journal of Roentgenology. 2015;204(4):798–803.
Rosenkrantz AB, Hindman N, Fitzgerald EF, Niver BE, Melamed J, Babb JS. MRI features of renal oncocytoma and chromophobe renal cell carcinoma. American Journal of Roentgenology. 2010;195(6):W421-W7.
Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010;7(5):277–85.
Takahashi M, Kume H, Koyama K, Nakagawa T, Fujimura T, Morikawa T, et al. Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET/CT. Clinical nuclear medicine. 2015;40(12):936.
Nakajima R, Nozaki S, Kondo T, Nagashima Y, Abe K, Sakai S. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using 18 F-fluorodeoxyglucose-positron emission tomography/computed tomography. European radiology. 2017;27(11):4866–73.
Wang H-Y, Ding H-J, Chen J-H, Chao C-H, Lu Y-Y, Lin W-Y, et al. Meta-analysis of the diagnostic performance of [18F] FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging. 2012;12(3):464.
Ramdave S, Thomas GW, Berlangieri SU, Bolton DM, Davis I, Macgregor D, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. The Journal of urology. 2001;166(3):825–30.
Abouzied MM, Crawford ES, Nabi HA. 18F-FDG imaging: pitfalls and artifacts. Journal of nuclear medicine technology. 2005;33(3):145–55. 14
Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M, et al. Relationship between retention index in dual-phase 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. Journal of Nuclear Medicine. 2002;43(2):173–80.
Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nature Reviews Cancer. 2002;2(9):683–93.
Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. Journal of Nuclear Medicine. 1995;36(10):1811–7.
van Berkel A, Rao JU, Kusters B, Demir T, Visser E, Mensenkamp AR, et al. Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma. Journal of Nuclear Medicine. 2014;55(8):1253–9.
Miyakita H, Tokunaga M, Onda H, Usui Y, Kinoshita H, Kawamura N, et al. Significance of 18F‐fluorodeoxyglucose positron emission tomography (FDG‐PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT‐1) expression in the cancer. International journal of urology. 2002;9(1):15–8.
Nakajima R, Abe K, Kondo T, Tanabe K, Sakai S. Clinical role of early dynamic FDG-PET/CT for the evaluation of renal cell carcinoma. European radiology. 2016;26(6):1852–62.
Ho C-l, Chen S, Ho KMT, Chan WK, Leung YL, Cheng KC, et al. Dual-tracer PET/CT in renal angiomyolipoma and subtypes of renal cell carcinoma. Clinical nuclear medicine. 2012;37(11):1075–82.
Bagheri MH, Ahlman MA, Lindenberg L, Turkbey B, Lin J, Civelek AC, et al., editors. Advances in medical imaging for the diagnosis and management of common genitourinary cancers. Urologic Oncology: Seminars and Original Investigations; 2017: Elsevier.
Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychological bulletin. 1979;86(2):420.
Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231(2):305–32.
Rigo P, Paulus P, Kaschten B, Hustinx R, Bury T, Jerusalem G, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. European journal of nuclear medicine. 1996;23(12):1641–74.
Aide N, Cappele O, Bottet P, Bensadoun H, Regeasse A, Comoz F, et al. Efficiency of [18 F] FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. European journal of nuclear medicine and molecular imaging. 2003;30(9):1236–45.
Sasson S, Kaiser N, Dan-Goor M, Oron R, Koren S, Wertheimer E, et al. Substrate autoregulation of glucose transport: hexose 6-phosphate mediates the cellular distribution of glucose transporters. 1997;40(1):30–9.
Özülker T, Özülker F, Özbek E, Özpaçaci T. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses. Nuclear medicine communications. 2011;32(4):265–72.
Mizuno T, Kamai T, Abe H, Sakamoto S, Kitajima K, Nishihara D, et al. Clinically significant association between the maximum standardized uptake value on 18 F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer. BMC cancer. 2015;15(1):114.
Yang Y, Valera VA, Padilla-Nash HM, Sourbier C, Vocke CD, Vira MA, et al. UOK 262 cell line, fumarate hydratase deficient (FH−/FH−) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer genetics and cytogenetics. 2010;196(1):45–55. 15
Lee H, Hwang KH, Kim SG, Koh G, Kim JH. Can initial 18F-FDG PET-CT imaging give information on metastasis in patients with primary renal cell carcinoma? Nuclear medicine and molecular imaging. 2014;48(2):144–52.
Gordetsky J, Zarzour J. Correlating preoperative imaging with histologic subtypes of renal cell carcinoma and common mimickers. Current urology reports. 2016;17(7):52.